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ber of exacerbations during the 6 month follow-up following initial exacerbation. 
We also compared health care utilization between both groups. Results: Among 
115,489 infants (mean age: 13.9 months; 62.9% boys), 4,477 infants of the MTL-4 
group were matched with 13,386 infants of the ICS group. In multivariate analysis, 
the risk of a new exacerbation was lower in infants of MTL-4 group compared to 
infants in ICS group (HR= 0.91, IC95% [0.87; 0.95]). The total number of exacerbations 
did not differ between the 2 groups during the 6-month follow-up (p= 0,8617), nei-
ther the cost of asthma management (344€ for MTL-4 group vs. 308€ for ICS group, 
p= 0.1410). ConClusions: MTL-4 and ICS appear to be comparable therapeutic 
strategies, with similar effects on exacerbation and equivalent costs. The SNIIR-AM 
allows conducting comparative effectiveness research.
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objeCtives: COPD is a disease that is characterized by chronic and progressive 
restriction of the airflow. The cost of COPD medications can be reduced signifi-
cantly by implementing a treatment algorithm that is consistent with the GOLD 
guidelines. Indacaterol and tiotrpium administered by inhalation are indicated for 
maintenance treatment of COPD in Turkey. We aimed to compare, from the perspec-
tive of the Turkish social security institution, the cost-effectiveness of indacaterol 
150 mcg once daily and long-acting tiotropium 18 mcg once daily at months 3 and 
6 in patients with moderate to severe COPD aged 30 years and above. Methods: 
From payer perspective, a cost-effectiveness analysis based on two separate clinical 
trials (INTENSITY-once daily indacaterol and tiotropium vs. placebo and INHANCE- 
indacaterol vs tiotropium) was performed. The primary endpoints of the clinical 
trials (Trough FEV1, Transition Dyspnea Index [TDI] and Saint Georges Respiratory 
Questionnaire [SGRQ]) were included in the cost-effectiveness analysis. Incremental 
cost effectiveness ratio (ICER) of indacaterol vs. tiotropium for different treatment 
success criteria (week 12 FEV1 > 0.12L increase, ≥ 1 improvement in TDI score, ≥ 4 
decrease in SGRQ score) were compared. Incremental cost effectiveness ratios were 
calculated over incremental differences versus placebo. Probabilistic sensitivity 
analysis was performed using the Bootstrap method. Results: FEV1success rates 
at month 3 for indacaterol and ipratropium were 26.5% and 24.3%, respectively. At 
month 3, ICERs of indacaterol versus ipratropium were -1002TL for FEV1, -434TL for 
TDI and -878TL for SGRQ. At month 6, FEV1 success rates were 54.8 and 47.4%, TDI 
success rates were 58.7% and 54.4% and SGRQ success rates were 81.8% and 77.1%, 
respectively. ICERs of indacaterol versus ipratropium at month 6 were -616TL for 
FEV1, -1049TL for TDI and -1014TL for SGRQ ConClusions: Based on this clinical 
trial-based analysis, indacaterol was cost effective treatment and cost reducing 
choice vs. tiotroprium in COPD treatment.
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objeCtives: Hospital-acquired pneumonia (HAP) is a severe respiratory tract infec-
tion which develops more than 48h after hospital admission. Ceftobiprole, the active 
moiety of its prodrug ceftobiprole medocaril, is a new cephalosporin with bactericidal 
activity against a broad spectrum of pathogens including resistant bacteria such as 
methicillin-resistant S. aureus (MRSA), penicillin-resistant pneumococci andP. aerugi-
nosa. Ceftobiprole was shown safe and effective for the treatment of HAP (excluding 
ventilator-associated pneumonia), when compared with linezolid plus ceftazidime 
in a large-scale phase-III clinical trial (NCT00210964). Methods: MEDLINE, EMBASE, 
Medline-In-Process and the Cochrane Library were searched for randomised con-
trolled trials that included ceftobiprole and/or comparators ceftazidime, meropenem, 
imipenem/cilastatin, piperacillin/tazobactam, ciprofloxacin, levofloxacin, moxifloxa-
cin and gentamicin as intervention in the treatment of HAP. The efficacy of ceftobi-
prole was compared to comparators using a random effects model implemented 
within a fully Bayesian framework. Primary outcome was clinical response after end 
of treatment in the clinically evaluable (CE) population. Results: Eleven studies 
(2413 patients) with HAP were included in the analysis, 1618 patients were eligible 
for analysis of clinical response in the CE population. The comparative efficacies 
(odds ratio, 95% credible intervals) of ceftobiprole to each comparator were 0.92,0. 
092-8.8 (ceftazidime), 1.1, 0.054-19 (piperacillin/tazobactam), 1.9, 0.12-30 (meropenem), 
0.83, 0.019-32 (levofloxacin), 0.96, 0.047-16 (imipenem/cilastatin), and 0.87, 0.025-22 
(ciprofloxacin). No comparison was possible to gentamicin or moxifloxacin due to 
a lack of comparative studies against other comparators. No significant difference 
was seen between ceftobiprole and any comparator in clinical response or in any of 
the secondary outcomes, including mortality and adverse events ConClusions: 
The results of this multi-treatment comparison support the comparable efficacy and 
safety of ceftobiprole to relevant comparators in the treatment of HAP. This analysis 
was limited by the small number of available studies, and by the fact that among the 
drugs compared, only ceftobiprole provides coverage of MRSA.
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concerning the long term safety and effectiveness of the drugs when used on larger 
populations. Pharmaceutical companies face big challenges for the coming years 
especially in EU and there is an increase need for local regulatory knowledge. There’s 
still need to increase awareness for the importance of real world studies and the 
impact it has on the patient’s life.
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The epidemiological and economic methods applied to health technologies evalu-
ations had a significant development in the last two decades. The need to balance 
the incorporation of new technologies in health care and limited financial resources 
promoted the construction and application of instruments supporting the decision 
making of health technology. The requirement Budget Impact Analysis formally 
stated in Law 12.401/2011 establishing the incorporation process technologies in 
SUS. In this context, in 2010/2011, the National Agency of Sanitary Surveillance 
(ANVISA) and DECIT, in partnership Institute for Health Technology Assessment 
(IATS) for drawing up of this guideline. In the first stage of development were 
used international recommendations of Canada, Australia, the UK and Poland, 
the recommendations of the International Society for PharmacoEconomics and 
Outcomes Research (ISPOR) and the methods used in studies of budgetary impact 
that had already been published. Afterwards, drafted a preliminary version of the 
Guideline and a standard tool - Excel worksheets - to estimate the uptake of mon-
etary resources required for adoption of new technologies. Revisions were carried 
out by technicians DECIT and health agencies, and the proposal was submitted to 
the Working Group on Development of Methodology REBRATS, composed of experts 
and academic researchers from several Brazilian states. Were also carried out work-
shops for the application of spreadsheets. In 2012, the first edition of the Guidelines 
was published two thousand copies in Portuguese in order to provide best practice 
recommendations for studies of budget impact.
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objeCtives: Accordance to Finnish Allergy Program 2008-2018, to decrease food 
avoidance diets by 50%. Focus in algorithm with patient history +IVD in school 
children with suspected food allergy and reason for declining re-diagnosis. NICE 
clinical guideline (Food Allergy Diagnoses, 2011) suggested further work made 
on effect of diagnosing allergies in realistic population and cost effectiveness of 
retesting. Methods: Prospective trial with patients from Finnish primary care 
database (2885 school children). School kitchen had allergy restricted diets for 179 
children. In the pilot phase, 179 families were contacted by letter. Of the 24 who 
were included in pilot, 17 were not allergic (70%). In this study families were inter-
viewed by telephone. Of 156 families 107 agreed to participate in this study and 
47 children will be diagnosed by component resolved diagnostics (CRD) and 60 
with sIgE and CRD. Results: Prevalence of food avoidance diets: 6,2%. Reasons for 
declining re-testing: 23 were not allergic, 9 were busy, 9 have own physician, 3 did 
not believe allergy tests, 8 scared of needles, 7 already tested, 4 tested often due to 
health problems, 2 in pilot study and 7 did not recognize a benefit. ConClusions: 
Telephone consultation by nurse decreased special diets for 23 children (13%) and 39 
(22%) had non-medical reason to decline retesting. Nurse consultation to introduce 
retesting with IVD can be considered as cost effective approach in decreasing food 
avoidance diets in children.
PRS2
effeCTiveneSS of MonTeluKaST on aSThMa ConTRol in infanTS:  
a ClaiMS daTa STudy
Belhassen M.1, Ginoux M.1, Laigle V.2, chanut-Vogel C.2, Lamezec L.2, de Blic J.3, Fauroux B.3, 
de Pouvourville G.4, Laforest L.1, Van Ganse E.1
1University of Lyon, Lyon, France, 2Laboratoires MSD France, Courbevoie, France, 3Pediatric 
Medicine Necker University, Paris, France, 4ESSEC Business School, Cergy, France
objeCtives: Montelukast 4mg (MTL-4) is an add-on therapy for asthmatic infants. 
Given the quality and exhaustivity of the data, French claims data (SNIIR-AM) is a 
relevant tool to investigate MTL-4 effectiveness in infants. The objective was to com-
pare the effectiveness of MTL-4, associated or not with ICS, vs. ICS without MTL-4, on 
health outcomes of infants with mild to moderate uncontrolled asthma. Methods: 
Infants (6-24 months) receiving ≥ 2 consecutive dispensing of respiratory drugs from 
2010 to 2011, and presenting an initial exacerbation within 6 months of the first 
dispensing were preselected. Asthma-related outcomes included hospitalizations, 
dispensing of oral corticosteroids, addition of short-acting beta agonists to exist-
ing respiratory therapy, switch to a higher ICS dosage, or nebulized CS. The studied 
groups were infants receiving MTL-4 +/- ICS (MTL-4 group) and infants receiving 
ICS without MTL-4 (ICS group). The two groups were matched, e. g. on initial therapy 
before initial exacerbation and past asthma related hospitalization. The two groups 
were compared, as to the occurrence of a new exacerbation and the total num-
